Actively Recruiting
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
Led by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Updated on 2026-03-30
230
Participants Needed
4
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the ALS/FTD disease spectrum, which includes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These two conditions share clinical, genetic, and pathological features and may even occur together in some patients. Diagnosis mainly depends on clinical symptoms, making it challenging. This study aims to discover new biological markers, called biosignatures, to improve diagnosis, patient classification, and monitoring of disease progression using advanced methods and multidisciplinary expertise.
CONDITIONS
Brief Title
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of ALS according to Brooks et al., 2000; de Carvalho M., 2008 criteria
- Clinical diagnosis of FTD according to Gorno-Tempini et al., 2011; Rascovsky et al., 2011 criteria
- Adults aged 18 years or older
You will not qualify if you...
- na
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants undergo extensive clinical and neuropsychological assessments, including the Burghart Sniffin' Sticks test, before sample collection.
Multiple visits for assessments and sample collection
Duration - Up to 24 months
Participants provide various biological samples including cerebrospinal fluid, blood, tears, skin, and olfactory mucosa for biomarker discovery and validation analyses.
Multiple visits depending on sample type and cohort assignment
Duration - Up to 24 months
Participants' data and samples are analyzed over time to identify disease biosignatures and understand disease progression in the ALS/FTD spectrum.
Follow-up assessments and sample collections as scheduled
Trial Site Locations
Total: 4 locations
1
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy, 20133
Actively Recruiting
2
Università degli Studi di Napoli "Federico II"
Naples, Italy, 80131
Not Yet Recruiting
3
Azienda Ospedaliero Universitaria di Sassari
Sassari, Italy, 07100
Not Yet Recruiting
4
Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP)
Sesto Fiorentino, Italy, 50019
Not Yet Recruiting
Research Team
F
Fabio Moda, phd
A
Arianna Ciullini, phd
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here